What is Vimizim (vosoritide) by BioMarin?
Vimizim is the brand name of vosoritide, an engineered drug developed by BioMarin for achondroplasia (a genetic form of dwarfism). It targets the underlying disease pathway by acting on the fibroblast growth factor receptor 3 (FGFR3) to help improve growth outcomes in children with achondroplasia.[1]
What conditions does Vimizim treat?
Vimizim is used in people with achondroplasia. Its clinical use is focused on improving growth (height and related growth measures) in the eligible pediatric population described in prescribing information and regulatory approvals.[1]
Who is eligible to use Vimizim?
Eligibility depends on the age range and diagnostic confirmation criteria set in the local label (for example, that the person has achondroplasia confirmed by appropriate genetic or clinical criteria). The exact age limits and patient selection details are contained in the official prescribing information for each market.[1]
How does Vimizim work?
Vimizim (vosoritide) works by modulating the FGFR3 pathway, which is central to achondroplasia biology. By addressing excess FGFR3 signaling, it aims to improve endochondral bone growth and height velocity in patients with achondroplasia.[1]
What side effects are associated with Vimizim?
Commonly reported adverse effects for vosoritide in achondroplasia include injection-site reactions and possible effects related to blood pressure and/or electrolytes depending on labeling. Exact frequency and severity are detailed in the product’s prescribing information.[1]
How is Vimizim given?
Vimizim is administered by injection. The route and dosing schedule follow the prescribing information for the specific country/region.[1]
Is Vimizim the only BioMarin treatment for this area?
BioMarin has multiple rare-disease therapies, but Vimizim is specifically for achondroplasia (vosoritide). If you meant another BioMarin product name, tell me the spelling you saw and I can map it to the correct drug.[1]
---
Sources
[1] https://www.vimizim.com/